Ardin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ardin

Quick Facts

Property Description
Active ingredient Loratadine
Form Oral tablet, syrup, or solution
Pharmacological class Second-generation Antihistamine
General purpose Relieves symptoms of histamine release
Origin Synthetic tricyclic compound

What is Ardin and What Pharmacological Class Does it Belong To?

Ardin is the trade designation for a medicine containing the active substance Loratadine. This substance is formally classified as a second-generation antihistamine, a categorization clinically recognized across numerous pharmacological studies. It belongs to the Pharmacological class of Histamine H1-receptor antagonists. As a synthetic, single-ingredient agent, it is manufactured as a tricyclic piperidine derivative specifically designed for systemic use via the oral route. Its second-generation status is a defining feature, signifying its highly selective affinity for peripheral receptors compared to older compounds.

What is Loratadine’s Composition and Why is it Non-Sedating?

The composition of the medicine is centered on Loratadine, which is prepared for intake as an oral syrup, solution, or tablet using a suitable pharmaceutical base. The key attribute of Loratadine is its limited ability to cross the blood-brain barrier, making it a desirable non-sedating agent. This characteristic is supported by pharmacological studies confirming its minimal sedative potential. Following administration, the substance undergoes metabolism to its active component, Desloratadine, which also contributes to the sustained systemic H1-receptor blockade across the body.

What is the General Purpose of Ardin?

The fundamental purpose of Ardin is to reduce or relieve the physiological symptoms that are triggered by the body’s release of histamine during a hypersensitivity reaction. The drug achieves this by maintaining a selective peripheral H1-receptor blockade, thereby inhibiting the action of histamine, the main chemical mediator of allergic reactions, throughout the body. This systemic approach provides comprehensive support against various manifestations of allergic discomfort.

Regulatory References

  1. U.S. National Library of Medicine, MedlinePlus

What side effects are possible with Ardin?

Possible Side Effects and Safety Information

The medicine Ardin (loratadine) has an official safety profile that classifies potential adverse reactions by both the frequency of occurrence and the specific system or organ affected, as defined by government regulatory authorities.

Adverse Reaction Classification

Side effects are most frequently reported within the Nervous System Disorders and General Disorders system-organ classes.

Classification Examples of Reactions Affected Systems (SOC)
Common (ge 1/100 to <1/10) Headache, somnolence, fatigue Nervous System, General Disorders
Uncommon Insomnia, increased appetite Psychiatric, Metabolism
Very Rare (<1/10,000) Tachycardia, convulsions, abnormal hepatic function, severe hypersensitivity reactions Cardiac, Nervous System, Hepatobiliary

Serious Adverse Reactions and Safety Constraints

Very rare but clinically significant adverse reactions documented in regulatory sources include severe systemic hypersensitivity reactions (such as angioedema and anaphylaxis), convulsions, and abnormal hepatic function.

The regulatory label provides specific constraints for use. The medicine is contraindicated in individuals with a known hypersensitivity to the active substance or any formulation component. Safety considerations are noted for specific populations:

  • Severe Hepatic Impairment: A lower initial dose is recommended for adults and children over 30 kg due to potentially reduced substance clearance.
  • Pediatric Use: Safety and efficacy have not been established for children under two years of age.
  • Lactation: Use is not recommended in breast-feeding women, as the substance is known to be excreted in breast milk.

Additionally, the label advises that the medication should be discontinued at least 48 hours before allergy skin tests, as it may inhibit or reduce the positive reactions.

Overdose and Emergency Response

Overdose and when to seek help

In the event of exposure to Loratadine (Ardin) doses exceeding regulatory limits, emergency medical help is mandated. Overdosage has been documented to increase the occurrence of systemic anticholinergic symptoms.

Documented Manifestations

Overdose manifestations reported in official documentation typically affect the nervous and cardiovascular systems, including:

  • Somnolence (drowsiness)
  • Tachycardia (fast heart rate)
  • Headache

In the pediatric population, specific signs such as Palpitations and Extrapyramidal signs have been reported following excessive syrup ingestion. The risk of somnolence is noted to be increased in the elderly and patients with hepatic or renal impairment.

Required Emergency Action and Management

If an overdose is suspected, official regulatory guidance requires the patient to seek immediate medical attention or contact a Poison Control Center right away.

Treatment is symptomatic and supportive, as no specific antidote is known. Procedures that may be considered by medical professionals include the administration of activated charcoal as a slurry with water, and gastric lavage. After initial emergency procedures, medical monitoring of the patient is required to be continued. The regulatory text specifies that Loratadine is not removed by haemodialysis.

Therapeutic Uses of Ardin

What Ardin Treats: Main Uses and Benefits

The primary therapeutic use of this medication is to provide supportive relief across several domains of allergic discomfort.

Relief from Seasonal and Year-Round Allergic Rhinitis

Ardin is commonly used to help manage symptoms related to acute or episodic changes that are characteristic of allergic rhinitis, a condition involving episodic or fluctuating manifestations. It is applied in addressing symptom clusters that may become intense or disruptive, such as sneezing, runny nose, nasal itching, and the ocular symptoms of itchy, watery eyes. This support helps ease the overall symptom burden during periods of heightened seasonal discomfort.

Management of Chronic Allergic Skin Reactions (Hives)

The medication is considered relevant for easing dermal allergic symptoms, including conditions like urticaria (hives). It is applied across therapeutic domains where additional symptomatic support is needed for addressing the symptom of intense skin itching (pruritus), as well as the appearance of associated raised welts or swelling. This assists with maintaining functional stability and supports patients during episodes of heightened discomfort.

Sustained, Non-Sedating Symptomatic Support

A relevant patient-oriented benefit may be the provision of continuous, symptomatic support for allergic conditions while maintaining a non-sedating profile. This generally supports patients during episodes of heightened discomfort and helps them cope more steadily with symptom fluctuations without compromising mental alertness.


Quick Fact: Relief for Eye, Nose, and Skin Symptoms Ardin supports patients by easing systemic symptoms related to heightened physiological activity. It is relevant for easing symptoms related to inflammatory or irritative states, including itchy/watery eyes, nasal discharge, and skin pruritus (itching) associated with allergic reactions.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Ardin?

This section outlines the officially documented population-eligibility rules for Ardin (Loratadine) as defined by government regulatory authorities.


Official Eligibility Summary

Classification Population/Condition
Standard Use Approved Adults, Adolescents, and Children mathbfge 6 years (for tablets/most forms).
Conditional Use Children mathbf2 to lt 6 years (typically for oral solution/syrup); Patients with severe hepatic or renal impairment; Older adults.
Use Not Recommended Breastfeeding mothers; Children mathbf< 2 years (safety/efficacy not established).
Contraindicated (Must Not Use) Individuals with a documented history of hypersensitivity (allergy) to Loratadine or any excipient in the specific formulation.

Eligibility Conditions and Restrictions

Ardin is mathbfabsolutely contraindicated for patients with a known hypersensitivity to the drug substance or its components. Eligibility for use in the pediatric population is age-dependent, with safety and efficacy mathbfnot established in children under 2 years of age. For adults with mathbfsevere liver or kidney impairment (GFR < 30 mL/min), use is restricted and requires caution, often necessitating a lower initial dose due to reduced clearance. Regulatory guidance also states that use during breastfeeding is generally mathbfnot recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines the interaction profile of Ardin (Loratadine) primarily through pharmacokinetic changes, resulting in altered systemic exposure of the drug.

Pharmacokinetic and Pharmacodynamic Interactions

The co-administration of Ardin with certain medicines that inhibit the CYP3A4 or CYP2D6 hepatic enzymes is associated with substantial increases in Loratadine’s plasma concentrations. Specific substances officially noted to cause this effect include the antibiotic Erythromycin, the antifungal Ketoconazole, and the H2-blocker Cimetidine. The regulatory profile also notes the potential for pharmacodynamic additive effects when Ardin is taken with other sedative drugs, which may reinforce symptoms like drowsiness.

Non-Medicinal and Population-Specific Interactions

Official findings state that the consumption of food increases the systemic bioavailability (AUC) of Loratadine by approximately 40% to 48%. Conversely, formal studies indicate that Ardin has no potentiating effects on psychomotor performance when administered concomitantly with alcohol. Regarding population-specific factors, patients with severe hepatic impairment are noted to experience significantly reduced clearance, resulting in a documented doubling of Loratadine’s systemic exposure.

Mechanism of Action

How Ardin Works

Ardin exerts its pharmacodynamic effects by engaging specific molecular targets to regulate overactive biological processes, leading to distinct physiological changes.


Cytokine Pathway Modulation

This mechanism centers on the regulation of excessive mediator activity, specifically through the suppression of key inflammatory signaling molecules, such as Interleukin-1 beta (IL-1beta). By limiting the expression or activity of IL-1beta, Ardin reduces the downstream catabolic and inflammatory signals, thereby contributing to the regulation of cellular processes.


Enzyme-Mediated Signal Inhibition

Ardin acts within domains involving enzyme-mediated signaling to suppress or initiate specific signaling sequences. This involves modifying early molecular steps, typically through the inhibition of an enzyme critical for the production or activation of pro-inflammatory factors. This interaction influences the signaling duration and magnitude, consequently shaping systemic physiological responses.


Regulation of Cellular Homeostasis

The drug influences feedback regulation to support a more regulated state within targeted biochemical pathways. Ardin engages mechanisms that modulate the balance between pro-anabolic and anti-anabolic processes within cellular environments, thereby modulating processes associated with tissue catabolism.

Dosage and Administration Information

The administration of Ardin is based on established protocols defining the standardized approach to its intake. The medicine is exclusively administered via the oral route across all approved formulations, which include conventional tablets, oral solutions, and orally disintegrating tablets (ODTs).


Administration Protocols

The standard dosing regimen for adults and children aged six years and older is 10 mg taken once daily. This once daily frequency maintains the drug's intended systemic action over a 24-hour period. For younger children, specifically those between the ages of two and under six years, the dose is generally 5 mg once daily, often supplied as an oral solution.

A key administration condition is that the medicine can be taken with or without food, allowing for flexibility in the daily schedule. Specific formulations require particular handling to ensure correct use. The oral solution must be accurately measured using a proper dosing device, not a common household spoon. For the orally disintegrating tablet, the instruction is to peel back the foil on the blister pack to remove the tablet, place it on the tongue, and allow it to dissolve before swallowing.


Special Dosing Instructions

Dose adjustments are required for certain populations. Individuals with severe liver disease or severe renal impairment (creatinine clearance < 30 mL/min) should follow an altered schedule, typically taking 10 mg every other day. If a scheduled dose is missed, standardized guidance instructs the user to take the next dose at the regularly scheduled time and not to double the dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ardin

Research into Ardin involves different types of studies, primarily focusing on its use in patients with osteoarthritis and on how it might relate to the cartilage in their joints. The evidence gathered so far helps us understand what has been explored, what has been found, and where more research is still needed.

The main type of study conducted for Ardin is the randomized controlled trial (RCT). This design allows researchers to examine differences between the group receiving Ardin and the group receiving the inactive substance (placebo). Other research involves combining the results of many of these trials—a method called a meta-analysis—to get a broader picture of the findings.


Osteoarthritis of the Knee and Hip

Research has explored Ardin in relation to symptoms associated with osteoarthritis in both the knee and hip joints. The main goal of these studies was to examine findings related to joint pain and difficulties with movement (physical function).

The primary research for this indication involves several placebo-controlled studies. When researchers look at all these studies together, the findings examined the difference in reported joint pain between the Ardin group and the placebo group. The results also reported a small difference in measured overall physical function of the joint when compared to the placebo group. These suggested differences are often measured over the short to medium term.

What remains uncertain is the observation of Ardin's effects over a very long period, such as several years. While studies suggest a possible difference in the joint cartilage structure, the long-term clinical significance of this finding is still an area that requires more comprehensive, long-lasting research.


Special Populations: Elderly Patients

Specific analyses focusing on elderly patients (often defined as those aged 65 or older) were conducted as part of the overall clinical trial program. The findings from these focused studies suggest that Ardin is associated with similar observed differences in joint pain and function for the elderly group compared to the general adult population.

However, research in very old or frail elderly patients remains limited. Therefore, evidence is limited regarding the effects of Ardin on the most frail or those with multiple other health conditions (comorbidities). Dedicated studies for these elderly subgroups are still needed.

Frequently Asked Questions (FAQ)

Common questions about Ardin (FAQ)


Q: How quickly should I expect Ardin to start working?

A: Studies on Ardin (loratadine) have examined the time it takes for symptom relief to begin. Official clinical data suggests that the onset of action, or the time before patients notice a change, typically occurs within one to three hours after taking the tablet formulation.


Q: Is it possible to take Ardin with vitamins or supplements?

A: Official regulatory documents do not specify common vitamins or general supplements as known interactions for Ardin. Official information suggests discussing all supplements and vitamins with a healthcare provider. This is because certain supplements might sometimes affect how the drug is metabolized or could reinforce side effects like drowsiness.


Q: Does Ardin interact with herbal remedies like St. John's Wort?

A: Official information indicates that certain herbal remedies may interact with Ardin. Specifically, remedies such as St. John's Wort that affect liver enzymes may reduce the overall effectiveness of the medication. It is a general recommendation to discuss the use of any herbal products with a healthcare provider.


Q: Can older adults safely use Ardin?

A: Research evidence suggests that observed differences in pain and function are similar for older adults compared to the general adult population. Regulatory sources describe that research remains limited regarding the effects of Ardin on the most frail or those with multiple other health conditions.


Q: Is Ardin known to interact with alcohol?

A: Formal clinical studies have specifically examined the combination of Ardin and alcohol. Official findings state that Ardin has no potentiated effects on psychomotor performance when administered at the same time as alcohol.


Q: Can Ardin cause changes in weight?

A: A potential change in weight is not listed as a common side effect in official regulatory documents. However, an 'increased appetite' has been reported as an uncommon adverse reaction during studies of the medicine.


Q: Does Ardin have a warning about sun exposure?

A: Official safety information notes that in rare cases, sensitivity to the sun or ultraviolet (UV) light can occur. This condition is known as photosensitivity and precautions are sometimes advised if prolonged sun exposure is expected.


Q: What happens if I forget to take Ardin for a day?

A: Regulatory guidance provides clear instructions regarding missed doses. Users are instructed to simply take the next dose at the regularly scheduled time and should never double the dose to try and make up for the one that was missed. The treatment schedule should then be resumed normally.


Q: How is Ardin different from [Name of similar drug]?

A: Ardin is the trade name for the active substance loratadine, which is classified as a second-generation antihistamine. Other medicines may belong to the same pharmacological class but contain different active ingredients, resulting in distinct mechanisms of action or side effect profiles as defined in their respective regulatory documents.


Q: Can Ardin be used for conditions not mentioned in the official description?

A: This resource strictly provides information only on the uses of Ardin that have been officially reviewed and approved by government regulatory agencies. The approved purpose of Ardin is to relieve the physiological symptoms triggered by the body’s release of histamine.


Q: How long does Ardin stay in your system after stopping?

A: Based on pharmacokinetic data (how the drug moves through the body), the active substance in Ardin is metabolized after administration. The drug and its resulting components can typically be found in the body's system for approximately three to seven days after the last dose is taken.


Q: Is Ardin generally considered safe for long-term use?

A: Official documents define the safety profile through observed adverse reactions, but they do not use the broad classification 'safe for long-term use.' Some authorized product monographs allow for use up to six months for certain populations, but continuous use should be reviewed by a healthcare provider.


Q: Will Ardin affect my ability to drive or operate machinery?

A: Official information notes that while Ardin is primarily classified as non-sedating, very rarely it may cause drowsiness or reduced alertness. Official information advises ensuring awareness of how the medicine affects an individual before performing tasks that require special attention, such as driving or operating machinery.


Q: Is Ardin a habit-forming medicine?

A: Ardin (loratadine) is not formally listed or categorized as a controlled substance by official regulatory agencies. This means it does not have a formal designation as a habit-forming medicine.


Q: Can Ardin affect sleep patterns?

A: Official safety information lists two potential side effects that relate to sleep patterns. Both 'insomnia' (difficulty sleeping) and 'somnolence' (drowsiness) are documented as potential adverse reactions, with drowsiness being classified as common and insomnia as uncommon.


Q: Does Ardin have any known effects on mental clarity?

A: Official safety information lists potential effects on the nervous system, such as headache and somnolence (drowsiness). Although the drug is classified as non-sedating, these types of effects can be associated with an impact on concentration or mental clarity.


Q: Why do some people stop taking Ardin?

A: People may stop taking Ardin for various reasons documented in regulatory sources. Reasons may include the completion of the treatment course or due to the experience of a side effect, such as the common effects of headache or drowsiness.


Q: How does Ardin compare in purpose to an over-the-counter medicine?

A: Ardin is the trade designation for the active substance loratadine, which is a second-generation antihistamine. In some countries, the active ingredient in Ardin is available without a prescription (over-the-counter) for the same approved purpose of relieving allergic symptoms.


Q: Is Ardin used in other countries under the same name?

A: While the active ingredient, loratadine, is approved and used globally across many countries, the trade designation 'Ardin' may be different outside of the regions where it is officially marketed under that specific name.


Q: Are there any patient registries or support programs related to Ardin?

A: Regulatory authorities require systems for patients and healthcare professionals to report adverse reactions, which is mandatory for all medicines and contributes to the ongoing safety monitoring of Ardin. This resource does not provide details on specific financial support or registry programs.


Q: How long does a typical course of Ardin treatment last?

A: The duration of treatment with Ardin is dependent on the specific medical condition. The duration of use should be defined according to the clinical context. For certain approved uses, some official product monographs allow for continuous use for up to six months for adults and children 12 years of age and older.


Q: Is Ardin considered a high-risk medication?

A: Ardin is categorized as a second-generation antihistamine. Its safety is defined by official classifications of adverse reactions, which document that most common side effects are mild, but also list very rare yet clinically significant adverse reactions that have been documented.

How should Ardin be stored and disposed of?

Official Storage Conditions

Regulatory documents mandate specific conditions to maintain the stability of Ardin (Loratadine). Tablets must be stored at Controlled Room Temperature, specifically between 20^circC and 25^circC (68^circF to 77^circF). The medicine must be protected from excessive moisture and light. For liquid formulations (syrup or solution), it is explicitly stated, “Do not freeze.” All forms must be kept in the original, tightly closed container.

Safety and Disposal Requirements

Storage must always comply with child-safety requirements: keep this medicine out of the sight and reach of children. For disposal of unused or expired product, the official labeling directs that it must not be thrown away via wastewater or household waste. Patients should consult a pharmacist or follow local regulations for proper pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ardin found in:

A-Z Index: